KRAS and metastatic malignant neoplasm: Previously we showed that ACT with TIL targeting KRAS mutation led to substantial tumor regression in a metastatic cancer patient7 and as KRAS mutations are highly prevalent among different cancer histologies (Supplementary Table 7), isolating TCRs targeting such mutations can be of high clinical relevance to a substantial portion of cancer patients.